Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization

S. Savastano, G. P. Feltrin, D. Neri, P. Da Pian, M. Chiesura-Corona, E. Roman, G. Battaglia, G. Gerunda, M. Lise, D. Miotto

Research output: Contribution to journalArticle

Abstract

Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.

Original languageEnglish
Pages (from-to)26-29
Number of pages4
JournalActa Radiologica
Volume34
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

Palliative Care
Hepatocellular Carcinoma
Survival
Absorbable Gelatin Sponge
Ethiodized Oil
Recurrence
Neoplasms
Ethanol
Injections
Therapeutics

Keywords

  • chemotherapeutic infusion
  • doxorubicin
  • gelatin foam
  • Hepatic arteries
  • iodized oil
  • liver neoplasms
  • Therapeutic blockade
  • therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Savastano, S., Feltrin, G. P., Neri, D., Da Pian, P., Chiesura-Corona, M., Roman, E., ... Miotto, D. (1993). Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization. Acta Radiologica, 34(1), 26-29. https://doi.org/10.1177/028418519303400106

Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization. / Savastano, S.; Feltrin, G. P.; Neri, D.; Da Pian, P.; Chiesura-Corona, M.; Roman, E.; Battaglia, G.; Gerunda, G.; Lise, M.; Miotto, D.

In: Acta Radiologica, Vol. 34, No. 1, 1993, p. 26-29.

Research output: Contribution to journalArticle

Savastano, S, Feltrin, GP, Neri, D, Da Pian, P, Chiesura-Corona, M, Roman, E, Battaglia, G, Gerunda, G, Lise, M & Miotto, D 1993, 'Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization', Acta Radiologica, vol. 34, no. 1, pp. 26-29. https://doi.org/10.1177/028418519303400106
Savastano S, Feltrin GP, Neri D, Da Pian P, Chiesura-Corona M, Roman E et al. Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization. Acta Radiologica. 1993;34(1):26-29. https://doi.org/10.1177/028418519303400106
Savastano, S. ; Feltrin, G. P. ; Neri, D. ; Da Pian, P. ; Chiesura-Corona, M. ; Roman, E. ; Battaglia, G. ; Gerunda, G. ; Lise, M. ; Miotto, D. / Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization. In: Acta Radiologica. 1993 ; Vol. 34, No. 1. pp. 26-29.
@article{54113712a41d450e83a25afa88d47f93,
title = "Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization",
abstract = "Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.",
keywords = "chemotherapeutic infusion, doxorubicin, gelatin foam, Hepatic arteries, iodized oil, liver neoplasms, Therapeutic blockade, therapy",
author = "S. Savastano and Feltrin, {G. P.} and D. Neri and {Da Pian}, P. and M. Chiesura-Corona and E. Roman and G. Battaglia and G. Gerunda and M. Lise and D. Miotto",
year = "1993",
doi = "10.1177/028418519303400106",
language = "English",
volume = "34",
pages = "26--29",
journal = "Acta Radiologica",
issn = "0284-1851",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization

AU - Savastano, S.

AU - Feltrin, G. P.

AU - Neri, D.

AU - Da Pian, P.

AU - Chiesura-Corona, M.

AU - Roman, E.

AU - Battaglia, G.

AU - Gerunda, G.

AU - Lise, M.

AU - Miotto, D.

PY - 1993

Y1 - 1993

N2 - Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.

AB - Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.

KW - chemotherapeutic infusion

KW - doxorubicin

KW - gelatin foam

KW - Hepatic arteries

KW - iodized oil

KW - liver neoplasms

KW - Therapeutic blockade

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84965846908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965846908&partnerID=8YFLogxK

U2 - 10.1177/028418519303400106

DO - 10.1177/028418519303400106

M3 - Article

AN - SCOPUS:84965846908

VL - 34

SP - 26

EP - 29

JO - Acta Radiologica

JF - Acta Radiologica

SN - 0284-1851

IS - 1

ER -